Basel Medical Group Ltd Ordinary Shares (BMGL) vs Xenetic Biosciences, Inc. (XBIO)

A side-by-side comparison of Basel Medical Group Ltd Ordinary Shares and Xenetic Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Basel Medical Group Ltd Ordinary Shares logo
BMGL
Basel Medical Group Ltd Ordinary Shares
$5M
$3.30HealthcareDelayed quote: Oct 6, 2026, 3:39 PM EDT
Xenetic Biosciences, Inc. logo
XBIO
Xenetic Biosciences, Inc.
$5M
$2.19HealthcareDelayed quote: Oct 6, 2026, 3:34 PM EDT

Total return — BMGL vs XBIO

growth of $100 · dividends reinvested · last 2y
BMGL -94.1% (-75.6%/yr)XBIO -44.9% (-25.7%/yr)XBIO compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $1002026$6$55
BMGL XBIO

BMGL vs XBIO: by the numbers

  • •BMGL is the larger company ($5M vs $5M market cap).
  • •Both run net losses; XBIO's is the smaller (-75.90% vs -106.78% net margin).

Metrics side by side

Valuation

MetricBMGLXBIO
P/S ratioN/A1.54
P/B ratio1.060.83

Profitability

MetricBMGLXBIO
Gross margin77.68%100.00%
Operating margin-19.28%-95.23%
Net margin-106.78%-75.90%
ROE-248.66%-40.76%
ROIC-35.07%-43.50%

Growth (annualized)

MetricBMGLXBIO
Revenue CAGR (5Y)N/A34.31%
Total return CAGR (5Y)N/A-34.54%

Go deeper

Full BMGL analysisFull XBIO analysisInteractive comparison tool

Dig into the metrics

Basel Medical Group Ltd Ordinary Shares ROEXenetic Biosciences ROEBasel Medical Group Ltd Ordinary Shares operating marginXenetic Biosciences operating marginBasel Medical Group Ltd Ordinary Shares revenue growthXenetic Biosciences revenue growthBasel Medical Group Ltd Ordinary Shares free cash flowXenetic Biosciences free cash flow

Basel Medical Group Ltd Ordinary Shares & Xenetic Biosciences appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.